Metastasis Affecting Patents (Class 514/19.8)
-
Publication number: 20110269686Abstract: The present invention provides preventive and/or therapeutic drugs for cancer and chronic rheumatoid arthritis which contain a peptide having a CXCR4 antagonism, its amide, its ester or its salt. Also, the present invention provides a novel peptide having a CXCR4 antagonism, its amide, its ester and its salt.Type: ApplicationFiled: July 8, 2011Publication date: November 3, 2011Applicant: BIOKINE THERAPEUTICS LTD.Inventors: Nobutaka FUJII, Hirokazu TAMAMURA, Akira HORI
-
Publication number: 20110268749Abstract: Disclosed herein are compositions and methods for treating or preventing cancer involving the use of a TNF-alpha antagonist, an IL-13R?2 antagonist, and/or a AP-I antagonist.Type: ApplicationFiled: July 31, 2008Publication date: November 3, 2011Applicant: The Government of the US as Represented by the Secretary Department of Health and Human ServicesInventors: Warren Strober, Jay A. Berzofsky, Stefan Fichtner-Feigl, Atsushi Kitani, Ivan J. Fuss, Masaki Terabe, Peter Mannon
-
Publication number: 20110269668Abstract: Disclosed are compounds and compositions of the formula I as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula I.Type: ApplicationFiled: October 13, 2009Publication date: November 3, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Alexander Heim-Riether, Shuang Liang, Sabine Schlyer
-
Publication number: 20110263513Abstract: Provided is the composition of a peptide and its mutagenic version, or other derivatives with the same 3-D structure with activity to bind the extracellular domain of PDGFR-?, or -?, but does not dimerize by itself, wherein said peptide comprises the sequence shown as SEQ ID NO: 1, 2 or 3. Also provided is the composition of the nucleotide sequence encoding said peptide and its derivatives, and the usage of said peptide and derivatives of the peptide in preparation of medicine for the prevention and treatment of fibrosis diseases, such as liver, kidney, and lung fibrosis, primary cancer, and cancer metastasis, especially stomach cancer, liver cancer, breast cancer, and lung cancer.Type: ApplicationFiled: September 21, 2009Publication date: October 27, 2011Inventors: Lan Huang, Hua Zhou, Shengtao Yuan
-
Publication number: 20110257102Abstract: A method of inhibiting neoplastic, cancer, and/or tumorgenic cell proliferation, cell growth and motility in a subject includes administering to a cancer cell expressing Pro-PrP and FLNa a therapeutically effective amount of a Pro-PrP regulating agent.Type: ApplicationFiled: December 23, 2009Publication date: October 20, 2011Inventors: Man-Sun Sy, Wei Xin, Chaoyang Li, Shuiliang Yi, Shaoman Yin
-
Patent number: 8039438Abstract: Synthetic peptides derived from sucrose synthase, and having homology to actin and actin-related proteins, sharing a common motif, useful for causing acting bundling and preventing actin depolymerization. Peptides exhibiting the common motif are described, as well as specific synthetic peptides which caused bundled actin and inhibit actin depolymerization. These peptides can be useful for treating a subject suffering from a disease characterized by cells having neoplastic growth, for anti-cancer therapeutics, delivered to subjects solely, or concomitantly or sequentially with other known cancer therapeutics. These peptides can also be used for stabilizing microfilaments in living cells and inhibiting growth of cells.Type: GrantFiled: October 20, 2004Date of Patent: October 18, 2011Assignees: The Regents of the University of California, North Carolina State University, U.S. Department of Agricultue/NCAURInventors: Heike Sederoff, Steven C Huber, Carolyn A Larabell
-
Patent number: 8034781Abstract: The present invention describes the use of angiotensin-(1-7) peptide as an anti-cancer therapeutic. Thus, in one embodiment, the present invention comprises a composition to inhibit the growth of cancer cells in an individual comprising a pharmaceutically effective amount of an agonist for the angiotensin-(1-7) receptor to inhibit cancer cell growth or proliferation. Application of a pharmaceutically effective amount of angiotensin-(1-7) or angiotensin-(1-7) receptor agonist is associated with an increase in the expression of genes involved in tumor suppression, apoptosis, and/or cell cycle inhibition, and a decrease the expression of known oncogenes, protein kinases, and/or cell cycle progression genes. Cancers treated using the methods and compositions described herein include cancers having an angiotensin-(1-7) receptor, including, but not limited to, breast and lung cancer.Type: GrantFiled: June 27, 2007Date of Patent: October 11, 2011Assignee: Wake Forest University Health SciencesInventors: E. Ann Tallant, Patricia E. Gallagher, Carlos M. Ferrario
-
Publication number: 20110236428Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.Type: ApplicationFiled: October 21, 2009Publication date: September 29, 2011Inventors: Christopher J. Kirk, Susan D. Demo, Mark K. Bennett
-
Publication number: 20110230423Abstract: The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered consecutively with said ligands, such as chemotherapeutic agents and or radiation therapy. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone, concurrently or not in the dosage regime of the present invention.Type: ApplicationFiled: November 13, 2009Publication date: September 22, 2011Inventors: Martin Andreas Picard, Christian Manegolo, Helen Wheeler, Mustafa Khasraw, Bart Neyns
-
Publication number: 20110229485Abstract: The subject matter of the present disclosure relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compounds to interact with neurotrophin 3 (NT-3 or NT3), to the extracellular domain, or TrkC receptor and/or to inhibit the dimerization of the intracellular domain of the TrkC receptor expressed in tumor cells, particularly in neuroblastoma. The disclosure also relates to a method for predicting the presence of metastatic cancer or a bad prognosis cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of neurotrophin 3. The disclosure further comprises kits and compounds as a medicament for the treatment of neuroblastoma or cancer overexpressing neurotrophin 3 by the tumor cells.Type: ApplicationFiled: May 22, 2009Publication date: September 22, 2011Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTFIQUE (CNRS), CENTRE LEON BERARD, ECOLE NORMALE SUPERIEURE DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1Inventors: Patrick Etienne Roger Mehlen, Servane Marie-séverine Tauszig-Delamasure, Céline Jacqueline-Andrée Delloye, Jimena Bouzas-Rodriguez
-
Publication number: 20110230397Abstract: Peptides and their functionally equivalent derivatives, in salified or non-salified form, with the general formula L1-X1—X2—X3—X4, wherein: L1 is H, or acyl, or any natural or non-natural amino acid, optionally N-acylated, N-alkylated and/or C?-alkylated; X1 and X3, which are equal or different, are any natural or non-natural basic amino acid, optionally N-alkylated and/or C?-alkylated; X2 is any natural or non-natural amino acid, optionally N-alkylated and/or C?-alkylated, with the proviso that it is not glycine and amino acids mono-substituted on the ? carbon atom with a linear or cyclic alkyl group, from 1 to 10 carbon atoms, and amino acids mono-substituted on the ? carbon atom with a linear or cyclic alkyl group containing 4 to 10 carbon atoms, or amino acids mono-substituted on the ? carbon atom with an alkyl group containing 1 to 8 carbon atoms, optionally substituted with a carbamoyl, hydroxyl or aromatic group; X4 is any natural or non-natural hydrophobic amino acid, optionally C?-alkylated and/orType: ApplicationFiled: July 19, 2007Publication date: September 22, 2011Inventors: Maria Vincenza Carriero, Mario De Rosa, Vincenzo Pavone
-
Publication number: 20110224150Abstract: The present invention relates generally to methods of effecting regression of tumor size and mass of a metastasized tumor in a subject by administering an effective amount of a desulphatohirudin variant.Type: ApplicationFiled: September 13, 2010Publication date: September 15, 2011Applicant: CANYON PHARMACEUTICALS, INC.Inventor: Cheng-Der Tony YU
-
Patent number: 7998934Abstract: A method is described for detecting, visualizing, or treating cells, particularly cancerous cells, that express a uPA/uPAR complex. The method employs a PAI-2 conjugate molecule that comprises PAI-2 or a functional derivative, homologue, analogue, chemical equivalent or mimetic thereof, which PAI-2 is bound, linked, or otherwise associated with a toxin or label.Type: GrantFiled: October 14, 2008Date of Patent: August 16, 2011Assignees: PAI-2 Pty Limited, University of Wollongong, Medical Scitec Australia Pty Ltd.Inventors: Marie Ranson, Barry John Allen, Clive Leighton Bunn
-
Publication number: 20110195902Abstract: The present invention provides an agent capable of inhibiting MMP-2 specifically. Disclosed is a fusion molecule composed of a ?-amyloid precursor protein molecule-derived domain having an activity of selectively inhibiting matrix metalloproteinase-2 and a tissue inhibitor of metalloproteinase capable of binding to latent matrix metalloproteinase. Also disclosed are a pharmaceutical composition, a cancer metastasis and/or angiogenesis inhibitor, a therapeutic and/or prophylactic for cardiovascular diseases, and a matrix metal loproteinase-2 inhibitor, each of which comprises the fusion molecule.Type: ApplicationFiled: October 5, 2009Publication date: August 11, 2011Applicant: ORIENTAL YEAST CO., LTD.Inventor: Shouichi Higashi
-
Publication number: 20110189131Abstract: The invention relates to active fragments of the IL-18 binding protein, to pharmaceutical compositions comprising such active fragments, and to medical uses thereof.Type: ApplicationFiled: March 29, 2011Publication date: August 4, 2011Applicant: MERCK SERONO SAInventors: VALTER ALTAROCCA, Anna R. Pezzotti
-
Publication number: 20110189120Abstract: The present invention relates to the discovery of the Aegyptin gene and Aegyptin protein, a molecule that interacts with collagen and inhibits platelet adhesion, activation and aggregation. Novel biological tools, prophylactics, therapeutics, diagnostics, and methods of use of the foregoing are also disclosed.Type: ApplicationFiled: July 7, 2008Publication date: August 4, 2011Applicant: USA DHHS- NIHInventors: Eric Calvo, Osvaldo Marinotti, Jose M.C. Ribeiro, Ivo M. Francischetti
-
Publication number: 20110190219Abstract: Methods for treating cancer (e.g., metastatic cancer to the lung or chronic lymphocytic leukemia) in patients are described that include administrating an aerosolized granulocyte macrophage colony stimulating factor to the patients. Methods for stimulating an immune response in patients also are described.Type: ApplicationFiled: March 7, 2008Publication date: August 4, 2011Inventor: Svetomir N. Markovic
-
Publication number: 20110182989Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.Type: ApplicationFiled: November 10, 2010Publication date: July 28, 2011Applicant: Allegro Pharmaceuticals, Inc.Inventors: Michael J. Mackel, John Park
-
Publication number: 20110171128Abstract: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides or conjugates. The present invention also relates to the use of these polypeptides for transporting a compound or drug across the blood-brain barrier of a mammal and in the treatment and diagnosis of neurological diseases.Type: ApplicationFiled: March 7, 2011Publication date: July 14, 2011Applicant: Angiochem Inc.Inventors: Richard BELIVEAU, Michel Demeule, Christian Che, Anthony Regina
-
Publication number: 20110158953Abstract: Disclosed are compositions and methods relating to Plexin C1 and diagnosing, treating, and evaluating treatment for cancer.Type: ApplicationFiled: June 17, 2009Publication date: June 30, 2011Applicant: UNIVERSITY OF ROCHESTERInventor: Glynis Scott
-
Publication number: 20110160147Abstract: The present invention relates to dual-targeting cytotoxic compounds of formula (I) and to their preparation. The described compounds are endowed with tumour specific action, incorporating three functional units: a tumour recognition moiety and a tumour selective enzymatic substrate sequence connected together by means of a spacer. These conjugates are designed to guarantee serum stability and, at the same time, the desired action inside the tumour cells as a result of enzymatic cleavability. [(L-D)nE]m-F-D-PI-SI-CT Formula (I).Type: ApplicationFiled: September 2, 2009Publication date: June 30, 2011Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventors: Alma Dal Pozzo, Emiliano Esposito, Minghong Ni, Sergio Penco, Claudio Pisano, Massimo Castorina, Loredana Vesci
-
Publication number: 20110143992Abstract: Disclosed herein are methods and compositions related to GHS-R antagonists.Type: ApplicationFiled: February 13, 2007Publication date: June 16, 2011Inventors: Dennis Taub, Vishwa Deep Dixit
-
Publication number: 20110144034Abstract: Described are methods for reducing tumor metastasis in an animal by administering an inhibitor of a protein kinase C (PKC) isozyme.Type: ApplicationFiled: December 22, 2010Publication date: June 16, 2011Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Daria D. Mochly-Rosen, Jeewon Kim, Steve Thorne
-
Patent number: 7960348Abstract: The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotropic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). By substituting the constituent amino acids of metastin with specific amino acids in the metastin derivative of the present invention, blood stability, solubility, etc. are more improved, gelation tendency is reduced, pharmacokinetics are also improved, and an excellent cancer metastasis suppressing activity or a cancer growth suppressing activity is exhibited. Furthermore, the metastin derivative of the present invention has the effects of suppressing gonadotropic hormone secretion, suppressing sex hormone secretion, etc.Type: GrantFiled: December 21, 2006Date of Patent: June 14, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Taiji Asami, Naoki Nishizawa
-
Publication number: 20110130344Abstract: The invention provides tight junction protein modulators, compositions comprising the same, and uses thereof. In particular, the invention provides tight junction protein modulators that modulate the second extracellular loop of tight junction proteins, such as occludin or claudin.Type: ApplicationFiled: February 9, 2011Publication date: June 2, 2011Applicant: The Regents of the University of Colorado, a body corporateInventors: Margaret C. Nerville, Robert S. Hodges, Neal Edward Beeman
-
Publication number: 20110118172Abstract: The invention provides a stable metastin derivative having excellent biological activities (a cancer metastasis-inhibiting activity, a cancer proliferation-inhibiting activity, a gonadotropin secretion-promoting activity, a sex hormone secretion-promoting activity, etc.). By replacing the constituent amino acids of metastin with specific amino acids in the metastin derivative of the present invention, the blood stability and solubility of the metastin derivative can be more improved, the gel tendency of the metastin derivative can be reduced, the pharmacokinetics of the metastin derivative can be improved, and the metastin derivative can exhibit an excellent cancer metastasis-inhibiting activity and cancer proliferation-inhibiting activity. The metastin derivative can also exhibit a gonadotropin secretion-inhibiting activity, a sex hormone secretion-inhibiting activity, etc.Type: ApplicationFiled: April 23, 2009Publication date: May 19, 2011Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Taiji Asami, Naoki Nishizawa
-
Publication number: 20110104263Abstract: The disclosure provides methods and compositions useful for treating claudin-4 associated disorders including cell proliferative disorders. The disclosure also provide claudin-family binding peptides useful in the methods of the disclosure.Type: ApplicationFiled: April 30, 2009Publication date: May 5, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: David D. Lo, Jun Ling, Mary M. Hamer, Thejani Rajapaksa
-
Publication number: 20110097388Abstract: This invention relates to methods of expressing eukaryotic proteins in prokaryotic hosts, particularly eukaryotic proteins that require formation of disulfide bridges for biological activity. Various approaches are used including fusion to thioredoxin, cytoplasmic expression of disulfide isomerases, deficiencies in thioredoxin and/or glutathione reductases, deficiencies in proteases, and the like. The method is applicable to express monomeric and dimeric forms of the eukaryotic protein with biological activity such as monomeric and dimeric forms of a disintegrin or a disintegrin domain. Included are the vectors, host cells expressing the proteins, the expressed proteins and methods of using the proteins.Type: ApplicationFiled: July 6, 2010Publication date: April 28, 2011Inventors: RADU O. MINEA, FRANCIS S. MARKLAND, JR.
-
Publication number: 20110077201Abstract: A cell-based screen is reported can be used to identify specific receptor-binding compounds in a combinatorial library of peptoids (N-alkylglycine oligomers) displayed on beads. This strategy was applied to the isolation of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)-binding peptoids, which were optimized to create lead compounds with high affinity for VEGFR2. One of these peptoids was shown to be an antagonist of VEGF-VEGFR2 interaction and receptor function.Type: ApplicationFiled: November 19, 2010Publication date: March 31, 2011Inventors: Thomas Kodadek, D. Gomika Udugamasooriya, Rolf Brekken
-
Publication number: 20110071089Abstract: The invention includes an isolated peptide comprising all or part of the amino acid sequence: EGKLSSNDTE GGLCKEFLHP SKVDLPR (SEQ ID NO: 1), wherein the peptide inhibits calcium channel activity. The peptides of the invention are useful for preventing or treating cancer.Type: ApplicationFiled: September 20, 2010Publication date: March 24, 2011Applicant: SORICIMED BIOPHARMA INC.Inventor: John M. Stewart
-
Publication number: 20110064828Abstract: The present invention generally relates to pharmacology and, in particular, to the treatment of tumors and other conditions. In some aspects, the invention is directed to the treatment of subjects having tumors or cancers that are metastatic. Surprisingly, it has been found that certain compositions comprising oxidized glutathione-based compounds are able to effectively treat such cancers by inhibiting cell migration and/or invasion processes, and thus, inhibiting tumor cell metastases. Without being bound by any theory, it is believed that such compositions are effective since the compositions are able to suppress the activation of critical signaling pathways within cells that are used for cell migration, such as the ErbB2 and/or phosphoinositide-3 kinase (PI3K) pathways, including the downstream RhoA and AKT pathways.Type: ApplicationFiled: September 10, 2010Publication date: March 17, 2011Applicants: Novelos Therapeutics, Incorporated, The Wistar InstituteInventors: Chris Pazoles, Evgeny Vulfson, Qihong Huang
-
Publication number: 20110059885Abstract: The method of the invention relates to an OmCI polypeptide or a polynucleotide encoding an OmCI polypeptide for the treatment of a disease or condition mediated by a leukotriene or hydroxyeicosanoid.Type: ApplicationFiled: February 5, 2009Publication date: March 10, 2011Inventors: Susan Lea, Miles Nunn, Pietro Roversi
-
Publication number: 20110053864Abstract: A peptide includes SEQ ID NO:3, substitution and addition variants thereof which maintain the ability to activate CD44. A complex includes this peptide or an ?6 polypeptide with a CD44 polypeptide. An isolated polypeptide includes the Link region sequence of human CD44, functionally active fragments thereof, substitution variants, and addition variants. A method of treating a disease characterized by aberrant cell migration and/or invasion includes administering to a subject an effective amount of the peptide of SEQ ID NO:3 or an ?6 polypeptide to bind to a CD44 polypeptide and modulate signal transduction activity for a sufficient period of time to treat the disease. Other methods include using the peptide of SEQ ID NO:3 or an ?6 polypeptide for diagnosing, identifying a subpopulation of subjects responsive to treatment, and screening for compounds that bind a CD44 polypeptide.Type: ApplicationFiled: March 5, 2010Publication date: March 3, 2011Applicant: ANGSTROM PHARMACEUTICALS, INC.Inventors: Malcolm Finlayson, Bassam B. Damaj
-
Publication number: 20110039785Abstract: The present invention is directed to polypeptide-nucleic acid conjugates. These conjugates can allow for targeted application of a therapeutic RNAi agent across the blood-brain barrier to treat, for example, a cancer, neurodegenerative disease, or lysosomal storage disorder.Type: ApplicationFiled: December 19, 2008Publication date: February 17, 2011Applicant: Angiochem Inc.Inventors: Richard Béliveau, Michel Demeule, Christian Che, Anthony Regina
-
Publication number: 20110039786Abstract: The present invention provides a metastin derivative represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, or a pharmaceutical composition containing it. The metastin derivative or a salt thereof is superior in blood stability, and has a cancer metastasis suppressive action or cancer growth suppressive action.Type: ApplicationFiled: April 28, 2009Publication date: February 17, 2011Applicants: KYOTO UNIVERSITY, TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Nobutaka Fujii, Shinya Oishi, Kenji Tomita
-
Publication number: 20110033461Abstract: Compositions which act synergistically to inhibit the growth of cancer cells and methods of use thereof are disclosed.Type: ApplicationFiled: March 12, 2009Publication date: February 10, 2011Inventors: Vladimir Ratushny, Erica Golemis, Igor Astsaturov, Iiya G. Serebriiskii, Louis M. Weiner
-
Publication number: 20110021442Abstract: The present invention discloses cell permeable RUNX3 recombinant proteins where a Macromolecule Transduction Domain (MTD) is fused to a tumor and metastasis suppressor RUNX3. Also disclosed are polynucleotides encoding the cell permeable RUNX3 recombinant proteins, an expression vector containing the cell permeable RUNX3 recombinant protein, and a pharmaceutical composition for preventing metastasis which contains the cell permeable RUNX3 recombinant protein as an effective ingredient. The cell permeable RUNX3 recombinant proteins of the present invention can induce the reactivation of TGF-? signal transduction pathway which causes cell cycle arrest by efficiently introducing a tumor and metastasis suppressor RUNX3 into a cell. Therefore, the cell permeable RUNX3 recombinant proteins of the present invention can be effectively used as an anticancer agent capable of preventing cancer growth and metastasis by suppressing the proliferation, differentiation, and migration of cancer cells.Type: ApplicationFiled: November 6, 2008Publication date: January 27, 2011Inventors: Daewoong Jo, Eun Kyung Hong, Jung-Hee Lim, Se-Eun Kang, Lihua Che
-
Patent number: 7871981Abstract: Disclosed are methods of inhibiting cell motility, for example, by inhibiting the binding between an intracellular transducer and a receptor protein tyrosine kinase, and more particularly by inhibiting hepatocyte growth factor (HGF) induced cell motility. The present invention also provides a method of inhibiting angiogenesis. The methods of the present invention employ peptides such as phosphotyrosyl mimetics. Also disclosed are methods of preventing and/or treating diseases, disorders, states, or conditions such as cancer, particularly metastatic cancer, for example, melanoma or prostate cancer, comprising administering to a mammal of interest one or more peptides of the present invention. Also disclosed are methods of blocking blocks HGF, VEGF, or bFGF-stimulated migration, cell proliferation, and formation of capillary-like structures.Type: GrantFiled: September 22, 2006Date of Patent: January 18, 2011Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Donald P Bottaro, Alessio Giubellino, Safiye N Atabey, Jesus V Soriano, Diane E Breckenridge, Terrence R Burke, Jr.
-
Publication number: 20110009313Abstract: A method of producing a polyethylene glycolated (PEGylated) lactoferrin complex having a linear polyethylene glycol (PEG) or a modified product thereof covalently bonded to lactoferrin via an amide bond includes causing a reaction to occur in a reaction liquid, which contains the lactoferrin and a linear PEG derivative having a para-nitrophenol leaving group, under conditions that allow formation of an amide group between the PEG derivative and the lactoferrin. A PEGylated lactoferrin complex contains a linear PEG or a modified product thereof covalently bonded to lactoferrin via an amide bond, and a pharmaceutical composition includes a PEGlyated lactoferrin complex, a therapeutically inert base, and/or an additive.Type: ApplicationFiled: March 13, 2009Publication date: January 13, 2011Applicant: NRL PHARMA, INC.Inventor: Atsushi Sato
-
Publication number: 20100323971Abstract: The present invention discloses cell permeable Nm23 recombinant proteins where a macromolecule transduction domain (MTD) is fused to a metastasis suppressor Nm23. Also disclosed are polynucleotides encoding the cell permeable Nm23 recombinant proteins, an expression vector containing the cell permeable Nm23 recombinant protein, and a pharmaceutical composition for preventing metastasis which contains the cell permeable Nm23 recombinant protein as an effective ingredient. The cell permeable Nm23 recombinant proteins of the present invention can induce KSR phosphorylation and inactivation and inhibit Ras-mediated MAPK cascade by efficiently introducing a metastasis suppressor Nm23 into a cell. Therefore, the cell permeable Nm23 recombinant proteins of the present invention can be effectively used as an anti-metastatic agent capable of preventing cancer metastasis by inhibiting the proliferation, differentiation and migration of cancer cells.Type: ApplicationFiled: September 4, 2008Publication date: December 23, 2010Applicant: PROCELL THERAPEUTICS INC.Inventors: Daewoong Jo, Thi Thuy Nga Do, Kisuk Park
-
Publication number: 20100305043Abstract: The invention relates to methods of treating cancer by administering one or more chemokines that are downregulated in cancerous cells. More specifically, the invention provides methods for treating or preventing cancers such as malignant melanoma by administering a chemokine such as CCL18 and/or CCL3. The invention further provides methods for diagnosing cancer such as melanoma.Type: ApplicationFiled: April 25, 2008Publication date: December 2, 2010Applicant: UNIVERISTY OF VERMONT AND STATE AGRICULTURAL COLLEGEInventors: Marcus Bosenberg, Christopher Matthew Bradbury, Ravikumar Muthuswamy
-
Publication number: 20100298234Abstract: The present inventors discovered that the neuromedin U receptor 2 (FM4) molecule is highly expressed in cancer cells such as pancreatic cancer cells. When the present inventors measured the proliferation-suppressing effect of ligands of this molecule against cancer cells, the ligands were found to have cancer cell proliferation-suppressing effects. The present inventors also discovered that this effect was produced by an FM4 molecule-mediated signal. These findings showed that ligands for the neuromedin U receptor 2 (FM4) molecule are effective for the treatment of cancers with enhanced expression of the neuromedin U receptor 2 (FM4) molecule, including pancreatic cancer, as well as for prevention of metastasis.Type: ApplicationFiled: August 15, 2007Publication date: November 25, 2010Inventor: Naoki Kimura
-
Publication number: 20100284935Abstract: The present invention provides methods for the prediction, prognosis and/or diagnosis of metastasis. The present invention also provides proteins (or the related nucleic acid sequences) or protein expression profiles which are predictive and/or prognostic for metastasis. The invention thus relates to the use of said proteins and the corresponding amino acid or nucleic acid sequences for the prediction, prognosis or diagnosis of metastasis.Type: ApplicationFiled: January 19, 2009Publication date: November 11, 2010Inventors: Bart Landuyt, Liliane Schoofs, Walter Luyten
-
Publication number: 20100286064Abstract: The present invention provides a polypeptide inhibiting the transmigration of leukocytes or the growth and/or metastasis of cancer cells, or a fusion protein thereof. The present invention also provides a polynucleotide encoding the polypeptide, a vector including the polynucleotide, and a transformant transformed with the vector. The present invention also provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases including the polypeptide or a fusion protein thereof. The present invention also provides a pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells including the polypeptide or a fusion protein thereof.Type: ApplicationFiled: September 20, 2006Publication date: November 11, 2010Inventors: Jang-Hee Hahn, Kyoung-Jin Lee, Dong-Min Kang
-
Publication number: 20100261653Abstract: In certain embodiments, this present invention provides polypeptide compositions, including compositions containing a modified polypeptide, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.Type: ApplicationFiled: September 14, 2009Publication date: October 14, 2010Applicant: VasGene Therapeutics, Inc.Inventors: Valery Krasnoperov, Nathalie Kertesz, Ramachandra Reddy, Parkash Gill, Sergey Zozulya
-
Publication number: 20100260827Abstract: The invention relates to methods and compositions for inhibiting metastasis, such as by inhibiting FOXC2 expression or activity. The invention further relates to methods of prognosticating, diagnosing, and assisting in the diagnosis of metastasis in an individual, or of determining the metastatic potential of a tumor. The invention further relates to methods of identifying agents which inhibit metastasis.Type: ApplicationFiled: December 28, 2006Publication date: October 14, 2010Applicant: Whitehead Institute for Biomedical ResearchInventors: Sendurai Mani, Jing Yang, Robert A. Weinberg
-
Publication number: 20100256073Abstract: The present invention relates to a pharmaceutical composition for the inhibition of cancer metastasis, more precisely, a novel pharmaceutical composition against cancer metastasis comprising lipocalin 2 protein, a gene encoding the protein, an expression vector containing the gene or cells transfected with the expression vector as an effective ingredient, a method for the inhibition of cancer metastasis using the composition, a diagnostic kit for the prediction of cancer metastasis, a method for the selection of a metastasis risk group using the kit, a novel pharmaceutical composition for the inhibition of cancer growth and a method for the inhibition of cancer growth using the same. The pharmaceutical composition of the present invention specifically inhibits cancer metastasis, so that it can improve the effect of cancer treatment dramatically.Type: ApplicationFiled: May 13, 2010Publication date: October 7, 2010Inventors: Eun-kyoung Lee, Ho-jeong Lee, Kong-ju Lee, Jang-seong Kim, Doo-hong Park, Yeup Yoon, Hyun-jun Kim, In-hwan Lim